== Adverse effects ==

 
The safety of desonide has not been determined beyond 4 weeks of use.<ref name=":1" /> Patients with allergies to corticosteroids (like hydrocortisone or prednisone) should use caution when taking desonide.<ref>{{Cite web|title = desonide topical : Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD|url = http://www.webmd.com/drugs/2/drug-4079-420/desonide-top/desonidecream-gel-ointment-topical/details#precautions|website = WebMD|accessdate = 2015-11-30|language = en-US}}</ref> Pharmacists and prescribing physicians should be aware that this medication may contain inactive ingredients than can cause allergic reactions.

 
Systemic absorption of topical corticosteroids can produce adverse effects. Indication of Cushing's syndrome, hyperglycemia, and glycosuria have been observed in some patients receiving treatment. After stopping treatment, reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency is possible. The cosyntropin (ACTH1-24) laboratory test can evaluate patients for HPA axis suppression.<ref name=":1" /> HPA function can be reversed after the cessation of treatment or replacement with another less potent corticosteroid. If glucocorticosteroid insufficiency occurs, supplemental systemic corticosteroids may be required.

 
Side effects of desonide requiring immediate contact with the prescribing physician:

 
Side effects that may go away as the body adjusts to the medication:

 
Recently, in late 2014, phase 3 clinical trials were completed to evaluate treatments using Desonide cream versus amino acid moisturizing cream.<ref>{{Cite web|title = A clinical trial to evaluate treatments using Desonide Cream and Amino Acid Moisturizing Cream for patients with Eczema or Atopic Dermatitis {{!}} Clinical Research Trial Listing  (Dermatitis, Atopic, Eczema) (NCT02286700)|url = http://www.centerwatch.com/clinical-trials/listings/external-studydetails.aspx?StudyID=NCT02286700|website = www.centerwatch.com|accessdate = 2015-12-01}}</ref> Patients with eczema or atopic dermatitis could be enrolled in this study, both male and female, over the age of 18. The randomized, double-blind, active control, 5-week study compared the effects of treatment of both creams through twice-a-day application. The clinical trial is sponsored by NeoStrata Company, Inc.

 
The first US. patent for desonide was US4185100A was granted on January 22, 1980.<ref>{{Cite web|title = Google Patents|url = https://patents.google.com/patent/US4185100A/en?q=desonide&sort=old|website = patents.google.com|accessdate = 2015-12-01}}</ref> The patent was for topical anti-inflammatory treatment using desonide. The patent defends the suitability of the anti-inflammatory for the treatment of cutaneous disorders or disruptions characterized by skin inflammation and/or hyperproliferative activity in the epidermis. Side effects and the mechanism of action are both disclosed. This patent is currently expired.
